Blood protein signatures could help doctors track TB treatment progress faster

Why it matters

Tuberculosis (TB) remains a major health problem worldwide, and doctors need reliable ways to know whether a patient’s therapy is working. The current standard—growing the bacteria in a lab (culture results)—takes weeks and often misses early signs of success or failure, leaving patients and clinicians uncertain about treatment effectiveness.

What the study found

A systematic review of 54 studies published up to September 2025 identified 105 distinct protein biomarkers in the blood and grouped them into seven categories: acute-phase proteins, inflammatory cytokines, innate immune markers, matrix remodeling enzymes, immune checkpoint molecules, angiogenic factors, and metabolic recovery proteins. The analysis showed that successful TB therapy is marked by a rapid drop in inflammatory markers, followed by changes in immune regulation and tissue‑repair pathways, while proteins linked to metabolic recovery rise over time. Combining several proteins into a multi‑protein biosignature (a set of biomarkers used together) gave a clearer picture of treatment response than any single marker alone.

What it means for people

Patients could receive quicker confirmation that their TB regimen is effective, reducing anxiety and the risk of unnoticed treatment failure. Clinicians gain a more timely tool to adjust therapy if needed, potentially improving outcomes and conserving resources. Researchers obtain a roadmap for developing blood‑based tests that reflect the body’s dynamic response to TB treatment.